Background: Phospholipases A 2 (PLA 2 ) are aggressive enzymes that can destroy phospholipids of cell membranes. The resulting cell fragments trigger the kallikrein-mediated contact phase of coagulation. The aim of the present study was to expose citrated whole blood to PLA 2 and to quantify thrombin generation in recalcifi ed plasma.
Introduction
Phospholipases A 2 (PLA 2 ) are aggressive enzymes and are found in high concentrations in blood of septic patients and in snake venoms [1] [2] [3] [4] [5] . After cell damage PLA 2 are released into the circulating blood. The recent specifi c and sensitive assay system for plasmatic thrombin, involving fi nal supramolar concentrations of arginine (to inhibit hemostasis and to depolymerize non-crosslinked fi brin) and fi nal chromogenic substrate concentrations below 0.6 mM (to detect only thrombin and not enzymes of the intrinsic phase of hemostasis) [6] was used to answer the question, if PLA 2 of different origin (bovine pancreas or snake) destroy blood cells, resulting in intrinsic thrombin generation by nonphysiologic cell fragments (e.g. polynegative niches in DNA or in phospholipid microparticles).
Material and Methods
2.1. Snake PLA 2 compared with LPS and ZyA 800 µl freshly drawn citrated blood (1 part of 106 mM citrate + 9 parts of venous blood) of 4 healthy donors was incubated in 1 ml Eppendorf-cups with 20 µl 8200 ng/ml LPS (fi nal conc. 200 ng/ml; LPS Drug Target Insights 2007: 2 83-96 from E. coli 0111;B4 purifi ed by gel fi ltration; Sigma, Deisenhofen, Germany; Article Nr. L 2637; 5 mg/ml stabilized in 0.5% human albumin (Kabi, Stockholm, Sweden) and freshly diluted for the experiment) in physiol. NaCl, 820 µg/ml (20 µg/ml final) zymosan A (ZyA; from Saccharomyces cerevisiae; Sigma; Article Nr. Z 4250) in physiol. NaCl, or 0-410 µg/ml (0-10 µg/ml fi nal) snake PLA 2 (1 mg/ml PLA 2 from Naja mossambica mossambica (Sigma; Article Nr. P 7778) in 5% human albumin and freshly diluted with physiol. NaCl) for 30 min or 45 min (RT). All healthy donors gave informed consent for studying the 4.5 ml citrated blood drawn into monovettes containing 0.5 ml 106 mM sodium citrate (Sarstedt, Nümbrecht, Germany). The cups were centrifuged in an Eppendorf-centrifuge at 10000 rotations/min for 5 min at 23°C. 50 µl of plasma was pipetted in duplicate into a microtitre plate with fl at bottom (F-well type C Polysorp ® ; NUNC, Wiesbaden, Germany; Article Nr. 446140). The hemolysis-control absorbance was measured at 405 nm with a microtitre plate reader with a 1 mA resolution (Milenia-DPC, Los Angeles, U.S.A.). 5 µl 250 mM CaCl 2 was added, using an Eppendorf-multipette with H 2 O-rinsed and completely emptied new tips. After 0-45 min coagulation reaction time (CRT at 37°C) 100 µl 2.5 M arginine, pH 8.6 (Sigma) was added. After 20 min (23°C) 50 µl 1 mM thrombin substrate HD-CHG-Ala-ArgpNA (CS-IIa; Pentapharm, Basel, Switzerland) in 1.25 M arginine, was added, the increase in absorbance per time (∆A/t) at 405 nm (23°C) was determined, and the results were standardized against the 1 IU/ml bovine thrombin (DadeBehring, Marburg, Germany) in 6.7% human albumin standard. From the hemolysis control it resulted that 1-10 µg/ml PLA 2 destroyed about 0.2-0.5% of erythrocytes (increase of basal plasma absorbance at 405 nm by 400-1000 mA).
1 ml citrated blood of a healthy donor was incubated with 10 µl 0-100 µg/ml (0-1 µg/ml fi nal conc.) snake PLA 2 in 0.5 % human albumin -0.9%. NaCl for 30 min (RT). After centrifugation 20 µl plasma was incubated in duplicate with 2 µl 250 mM CaCl 2 in U-well microtitre plates (NUNC) for 0-20 min CRT (37°C). 20 µl 2.5 M arginine was added. After 20 min (RT) 20 µl 0.77 mM CS-IIa in 2.3 M arginine, pH 8.6, was added and ∆A/t was measured. The experiment was repeated with a CRT of 40 min (37°C) for n = 4 different healthy donors.
Pancreas PLA 2 compared with LPS and ZyA
The experiment of 2.1. was repeated with blood of 4 healthy donors and with PLA 2 from bovine pancreas (Sigma; Article Nr. P 8913) in 2% human albumin and with final concentrations of 0-1000 ng/ml PLA 2 , 200 ng/ml LPS, or 20 µg/ml ZyA.
2.3. Pancreas PLA 2 versus LPS, ZyA without or with hydrocortisone 400 µl citrated blood of n = 4 healthy donors (3 h RT old) was added in duplicate to 10 µl 0-12300 ng/ml (fi nal blood conc. 0-300 ng/ml) bovine pancreas PLA 2 in 2% human albumin, 10 µl 410 ng/ml LPS (fi nal blood conc. 10 ng/ml) or 4100 ng/ml LPS (fi nal blood conc. 100 ng/ml) in 2% human albumin, 10 µl 410 µg/ml zymosan A (final blood conc.10 µg/ml) in 2% human albumin, or 10 µl 410 µg/ml zymosan A with 1 µl 100 mg/ml hydrocortisone (fi nal blood conc. 243 µg/ml) (Pfi zer, Karlsruhe, Germany). The samples were vortexed and after 30 min (RT) they were centrifuged for 5 min at 10000 rpm in an Eppendorf-centrifuge. 4 × 50 µl plasma were withdrawn and pipetted into a polystyrole fl at bottom microtiter plate (F-well type F, NUNC). 5 µl 250 mM CaCl 2 was added with an Eppendorfmutipette using H 2 O rinsed new disposable tips. After 5 min, 10 min, 15 min, 20 min CRT (37°C) 100 µl 2.5 M arginine, pH 8.6, was added. After 20 min (RT) 50 µl 0.91 mM chromogenic thrombin substrate HD-CHG-Ala-Arg-pNA in 1.36 M arginine (10 µmoles + 5 ml H 2 O + 6 ml 2.5 M arginine, pH 8.6) was added and ∆A at 405 nm (RT) was determined with a microtiterplate reader with a 1 mA resolution. The results were standardized against the 1 IU/ml bovine thrombin calibrator in 6.7% human albumin, replacing the plasma sample. 1 IU/ml thrombin had 14 mA/min RT, the maximal ∆A was 1400 mA, the linear range was up to 40% of 1400 mA = 560 mA.
Bovine pancreatic PLA 2 at 10 µg/ml
The experiment of 2.3. was performed with 20 ng/ml fi nal conc. LPS, 2 µg/ml fi nal conc. ZyA, 2% human albumin, 0.1 µg/ml, 1 µg/ml, 10 µg/ml PLA 2 .
2.5. Plasma replacing whole blood 2.5.1. Pooled normal plasma 160 µl pooled normal plasma (standard human plasma ® ; DadeBehring) was incubated with 20 µl LPS (final conc. 100 ng/ml, ZyA (final conc. 10 µg/ml), or PLA2 (fi nal conc. 0.1 µg/ml, 1 µg/ml, 10 µg/ml) in 1 ml Eppendorf-cups for 45 min (RT). 20 µl samples were withdrawn and pipetted into U-wells. The samples were recalcifi ed (10+1) with 2 µl 250 mM CaCl2. 50 µl 2.5 M arginine, pH 8.6, stopped the CRT after 0-30 min (37°C). After 20 min (RT) 25 µl 0.91mM CS-IIa in 1.36 M arginine was added and ∆A/t at 405 nm (RT) was determined. The calibrator 1 IU/ml thrombin had 3.7 mA/min RT.
Fresh normal plasma
190 µl of freshly drawn citrated plasma (<2 h RT old) from one healthy donor with proper venipuncture and one healthy donor with improper venipuncture and 5 min venous stasis time was incubated with 10 µl 2% human albumin, or fi nal conc. of 0.2 µg/ml PLA 2 , 2 µg/ml PLA 2 , 20 µg/ml PLA 2 , 250 ng/ml LPS, 2.5 µg/ml LPS, 25 µg/ml LPS, 250 µg/ml LPS, 10 µg/ml ZyA, 100 µg/ml ZyA for 45 min (RT) in 1 ml Eppendorf-cups. After centrifugation, 20 µl samples were pipetted into U-well microtitre plates and analyzed in duplicate as described in 2.5.1.
Statistics
The intra-assay coeffi cients of variation (CV), as defi ned as standard deviation divided by mean value and multiplied by 100%, of the thrombin generation values measured were <8%. The data points were compared to the respective controls and tested for signifi cance (p < 0.05), using the two-fold Yates-corrected chi-square comparison against the control-mean (X 2 0 Test) [7] .
Results
Figures 1a-d are the assay results of n = 4 healthy donors, each graphic representing one individual donor. They demonstrate that 100 ng/ml snake PLA 2 activates hemostasis similarly as 200 ng/ml LPS or 20 µg/ml ZyA in 3 of 4 healthy donors. 1000 ng/ml PLA 2 might result into lower (Fig. 1a-e) or similarly high (Fig. 1f,g ) thrombin activities comparable to 100 ng/ml PLA 2 . Thrombin generation in the recalcifi ed coagulation activity assay (RECA) also depends on the nature of the reaction well: fl at bottom polystyrole wells (F-wells) possess a different surface to polystyrol U-wells. This might explain the different thrombin generation in Fig. 1a-d (F-wells) when compared to Fig. 1e (U-wells) .
Also PLA 2 from bovine pancreas activates coagulation (Fig. 2) . At 15 min coagulation reaction time 10-100 ng/ml PLA 2 generate about 0.2-0.8 IU/ml thrombin. 1000 ng/ml pancreas PLA 2 at 15 min CRT behaves like 0 ng/ml pancreas PLA 2 . Coagulation reaction times >15 min (37°C) seem to result into activation of hemostasis, presumably by interaction of the plasma with the polystyrol of the microtiter plate. Fig. 2e shows the thrombin generation in the initial phase (CRT = 10 min) by pancreas PLA 2 as compared with that by snake PLA 2 (Fig. 1e) .
Up to 60 ng bovine pancreatic PLA 2 added per ml blood the generated thrombin activity is proportional to the PLA 2 activity used (Fig. 3a-c) : at 15 min CRT about 0.1-0.8 IU/ml thrombin is generated in 3 of 4 healthy donors; the blood hemostasis system of one donor (♦) behaved as resistant against PLA 2 attack. At PLA 2 concentrations ≤ 60 ng/ml the basal absorbance increase of plasma due to lysis of erythrocytes was <100 mA, i.e. < 0.05% of erythrocytes were lysed. Hydrocortisone at about 200 µg/ml blood concentration does not inhibit the hemostasis activation by 10 µg/ml zymosan A (Fig. 3d-f ). This means that the antiinfl ammatory agent hydrocortisone does not inhibit the hemostasis activation potency of extracellular PLA 2 . Figure 4 demonstrates that bovine pancreatic PLA 2 at a very high concentration (10 µg/ml fi nal) again results into pronounced hemostasis activation with about 0.1-3 IU/ml at 10-15 min CRT. However, in one of four patients 0.1 µg/ml PLA 2 induced more thrombin than 10 µg/ml PLA 2 (17 min CRT: 0.29 IU/ml versus 0.12 IU/ml) (Fig. 4b) .
In commercially available lyophilized pooled normal plasma there is no signifi cant increase in thrombin activity when exposed to up to 10 µg/ml bovine pancreatic PLA 2 (Fig. 5a ). Fresh plasma of the donor with proper venipuncture shows no thrombin generation by PLA 2 or LPS, only by extreme concentrations of ZyA (100 µg/ml) (Fig. 1a-c ) or a donor with acute bacterial tonsillitis (CRP = 21 mg/l) (Fig. 1d) was incubated in 1 ml Eppendorf-cups with fi nal concentrations of 200 ng/ml LPS (•), 20 µg/ml ZyA (▲), or 10 µg/ml (*),1 µg/ml (x), 0.1 µg/ml (+), 0 µg/ml (O) snake PLA 2 for 30 min (RT). After centrifugation 50 µl of plasma was pipetted into microtitre plates with fl at bottom. 5 µl 250 mM CaCl 2 was added. After 0-45 min coagulation reaction time (CRT) 100 µl 2.5 M arginine, pH 8.6, was added. After 20 min (RT) 50 µl 1 mM CS-IIa in 1.25 M arginine, was added, ∆A at 405 nm was determined, and the results were standardized against the 1 IU/ml thrombin in 6.7 % human albumin calibrator. Fig. 1e : 10 min CRT values of Figs. 1a-d; each donor has an individual symbol (•,▲,♦,■). 1 ml citrated blood of a healthy donor was incubated at fi nal conc. of 0 µg/ml (O), 0.1 µg/ml (■), 1 µg/ml (•) snake PLA 2 for 30 min (RT) (Fig. 1f) . After centrifugation 20 µl plasma was incubated with 2 µl 250 mM CaCl 2 in U-well microtitre plates for 0-20 min CRT (37°C). 20 µl 2.5 M arginine was added. After 20 min (RT) 20 µl 0.77 mM CS-IIa in 2.3 M arginine, pH 8.6, was added and ∆A/t was measured. The experiment was repeated with a PLA 2 preincubation time of 45 min and a CRT of 40 min for n = 4 healthy donors; each donor has an individual symbol (•,▲,♦,■ ) (Fig. 1g) . The experiment of fi gure 1 was repeated with blood of 4 healthy donors (Fig. 2a-d ) and with PLA2 from bovine pancreas at fi nal concentrations of: 0 ng/ml (O), 10 ng/ml ( ), 100 ng/ml (grey ), 1000 ng/ml PLA 2 (■), or 200 ng/ml LPS (*), 20 µg/ml ZyA (+). 400 µl citrated blood of n = 4 healthy donors (3 h RT old; •,▲,♦,■) was added to fi nal blood conc. of 0-300 ng/ml bovine pancreas PLA 2 . After 30 min (RT) the samples were centrifuged for 5 min at 10000 rpm, 50 µl plasma was recalcifi ed by 5 µl 250 mM CaCl 2 . After 10 min (Fig. 3a) , 15 min (Fig. 3b) , 20 min (Fig. 3c ) coagulation reaction time (CRT at 37°C) 100 µl 2.5 M arginine, pH 8.6, was added. After 20 min (RT) 50 µl 0.91 mM CS-IIa in 1.36 M arginine was added and ∆A at 405 nm (RT) was determined. The results were standardized against the 1 IU/ml bovine thrombin calibrator in 6.7 % human albumin, replacing the plasma sample. Fig. 3d -f: 400 µl citrated blood of 4 healthy donors was incubated for 30 min (RT) with human albumin (O), 10 ng/ml LPS ( ), 100 ng/ml LPS (■), 10 µg/ml ZyA (x), 10 µg/ml ZyA + 243 µg/ml hydrocortisone (*). Then the samples were zentrifuged, recalcifi ed, and analyzed as described in Fig. 3a-c; Fig. 3e : haemolytic blood. The experiment of fi gure 3 was performed with 20 ng/ml LPS ( ), 2 µg/ml ZyA (x), human albumin (O), 0.1 µg/ml (grey∆), 1 µg/ml (greyO), 10 µg/ml PLA 2 (•) in 4 normal donors ( Fig.4a-d ). (Fig. 5b) and one healthy donor with improper venipuncture and 5 min venous stasis time (Fig. 5c ) was incubated with 10 µl 2 % human albumin (O), or fi nal conc. of 0.2 µg/ml PLA 2 (▲), 2 µg/ml PLA 2 (■), 20 µg/ml PLA 2 (•), 250 ng/ml LPS (-), 2.5 µg/ml LPS (+), 25 µg/ml LPS (×), 250 µg/ml LPS (*), 10 µg/ml ZyA (grey∆), 100 µg/ml ZyA (grey O) for 45 min (RT) in 1 ml Eppendorf-cups. After centrifugation, 20 µl samples were pipetted into U-well microtitre plates and analyzed in duplicate as described in Fig. 5a . additional thrombin is generated (Fig. 5b) . In fresh plasma of the donor with poor venipuncture and 5 min stasis time hemostasis is activated by PLA 2 , LPS, and ZyA, when compared to the zero control (Fig. 5c ).
Discussion
Phospholipase A 2 activates hemostasis in whole blood. This pathophysiology of PLA 2 can already be observed at PLA 2 concentrations in the range of 10-100 ng/ml. Higher concentrations might increase or decrease hemostasis activation. This might be due to different effects of PLA 2 on whole blood: on the one hand PLA 2 destroys cells, and the cell fragments activate the contact phase of hemostasis, on the other hand PLA 2 inhibits certain phospholipid-dependent pathways of coagulation [8] [9] [10] [11] [12] , the intrinsic pathway is more susceptible than the extrinsic one [13] , and the activation of the prothrombinase by factor Xa is inhibited by PLA 2 [14] . PLA 2 interacts with hemostasis by its enzymatic acitivity or by its binding to critical hemostasis components [8] . Blood hemostasis seems to be especially susceptible to very low blood fl ow, such as when drawing blood after prolonged venous stasis (Fig. 5c ): the contact system of hemostasis might be activated thereby, this activation is enhanced by PLA 2 , LPS, or ZyA. Among healthy individuals there appears some variability of resistance against extracellular PLA 2 or LPS [6] : some human beings seem to be more susceptible against these triggers of intrinsic thrombin generation than others. It would be of particular interest characterize physiologic PLA 2 or LPS inhibitors or inhibitors of non-physiologic polynegative niches.
Not all of the PLA 2 molecules found in patient plasmas may have the same cell killing power, some PLA 2 enzymes might act preferentially as signal enzymes (e.g. the platelet PLA 2 ), others as membrane destructors (e.g. the pancreas PLA 2 ). Furthermore, some PLA 2 molecules in plasma might be present in a cryptic (inactive) form, another folding by matrix change (e.g. dilution) or enzyme action on them might activate them.
The present data support the pathophysiologic importance of PLA 2 in disseminated intravascular coagulation (DIC): some pathogenetic aspects of DIC seem to be similar to a snake bite: pathologic PLA 2 activities in blood can occur by a wide range of diseases [1] [2] [3] [4] [5] , many of them can give rise to PDIC. In PDIC an about 10-100 fold increase of the normal plasmatic PLA 2 activity can be found [15, 16] . It is suggested to screen patients for plasmatic thrombin generation to stop the pathogenesis of PDIC in time. Of particular importance could be physiologic inhibitors of PLA 2 [17] or of intrinsic thrombin generation [18] .
